Arcutis Earnings Call Signals Strong Growth, Bigger 2027 Ambitions
at www.tipranks.com (Sat, 14-Nov 8:43 PM)
Arcutis enrolls first patient in a 415-participant Phase 3 study of ZORYVE cream 0.3% for moderate to severe atopic dermatitis
Market Chameleon (Thu, 5-Nov 8:18 AM)
ARQT rallies after new ZORYVE infant and psoriasis data highlight rapid itch relief and broad efficacy
Market Chameleon (Fri, 9-Oct 11:47 AM)